AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Abstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas.
"These abstracts provide insights into the potential beneficial hematological effects of epetraborole across both clinical and nonclinical studies and strengthen our understanding of the exposure-response relationships that we believe support its development in polycythemia vera," said George H. Talbot, M.D. Co-Founder and Senior Medical Advisor of AN2 Therapeutics.
